Skip to Content

Intuitive Surgical Inc ISRG Stock Quote

| Rating as of


Morningstar‘s Stock Analysis ISRG

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


With Market Expectations Around System Placements Reset, Intuitive's Q3 Should Be Viewed Positively

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

As was the case with many growth companies, Intuitive's shares had been battered earlier in the year, down nearly 50% off their peak. Aside from the general rerating of high-growth firms, the market was also digesting Intuitive's revenue growth deceleration, which was mainly attributable to declining systems placements. With expectations around a systems growth reset (a trend we've been highlighting for quite some time now), the company's third-quarter results should be viewed favorably as many key value drivers for the business remain intact. As shares currently trade in 3-star territory, valuation is no longer unreasonable. We maintain our wide moat rating and $204 fair value estimate.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ISRG

Company Profile ISRG

Business Description

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.

1020 Kifer Road
Sunnyvale, CA, 94086-5304
T +1 408 523-2100
Industry Medical Instruments & Supplies
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 9,793

Related News ISRG